birinapant

Ligand id: 7432

Name: birinapant

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 14
Hydrogen bond donors 8
Rotatable bonds 19
Topological polar surface area 194.92
Molecular weight 806.43
XLogP 2.47
No. Lipinski's rules broken 3

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Birinapant is being assessed in clinical trials to test effectiveness in patients with various types of cancer, either alone or in combination with other chemotherapeutic drugs. ClinicalTrials.com lists all currently registered trials using this compound.
Mechanism Of Action and Pharmacodynamic Effects
Birinapant is a small molecule peptidomimetic of SMAC (second mitochondrial-derived activator of caspases) that selectively targets IAPs (inhibitors of apoptosis) and inhibits their activity. The compound effectively turns off NF-κB pro-survival signalling and synergises with pro-apoptotic ligands (eg TNFα and TRAIL) to direct cells towards the caspase-dependent pro-apoptotic pathway [1-4]. Birinapant exhibits somewhat selective binding activity for cellular inhibitor of apoptosis 1 (cIAP1) compared to cIAP2. Birinapant also antagonizes the function of XIAP (X-linked inhibitor of apoptosis) which permits activation of the caspases which terminate the extrinsic and intrinsic apoptosis pathways.